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Background: Few studies exist that evaluate the therapeutic response among switchers of tumor necrosis
antagonists in patients with psoriasis, especially Asian patients.
Objective: This study aimed to evaluate the safety and effectiveness of adalimumab in patients with
moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept.
Methods: This is a single-center, open-labeled, retrospective study on the effects of adalimumab in
patients with moderate-to-severe psoriasis who had inadequate therapeutic responses to prior eta-
nercept. We included 13 patients who had received etanercept for at least 3s months but showed
inadequate therapeutic response, as deﬁned by less than 50% improvement in psoriasis area and severity
index (PASI) 50, compared to baseline after 6 months or less than PASI25 improvement after 3 months in
our hospital during 2006e2012. Adalimumab 40 mg was given every other week with a loading dose of
80 mg. Patients were evaluated monthly for safety and effectiveness. PASI, physician global assessment,
and scores of scalp lesions were calculated at Weeks 12 and 24. Scalp lesions were assessed separately.
Results: At Week 12, one patient (7%) had at least PASI90, two (15%) had at least PASI75, four (31%) had at
least PASI50, and eight (61.5%) had at least PASI25 response. At Week 24, two patients (15%) had at least
PASI90, three (23%) had at least PASI75, six (46%) had at least PASI50, and nine (69%) had at least PASI25
response. No severe adverse events were recorded in our series. For scalp lesion, adalimumab showed
similar efﬁcacy to etanercept nonresponders.
Conclusion: Safety proﬁles of adalimumab were similar to those of etanercept, and PASI50 was achieved
in 46% of patients, who failed prior etanercept therapy, after 24 weeks of adalimumab treatment.
Copyright  2012, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Both etanercept and adalimumab are tumor necrosis factor (TNF)
antagonists that show favorable therapeutic responses in psoriasis
and psoriatic arthritis (PsA). However, these two drugs have
a slightly different mode of action and treatment response. Few
studies exist that evaluate the therapeutic response of psoriasis
among the switchers of these two TNF antagonists, especially
among Asians. This is a single-center, open-labeled, retrospective
study on the effects of adalimumab in patients with moderate-to-
severe psoriasis who had inadequate therapeutic responses to
prior etanercept.y, National Taiwan University
iwan. Tel.: þ886 2 23562141;
iwanese Dermatological AssociatioMethods
We included patients who had received etanercept 25 or 50 mg
BIW subcutaneous injection for at least 3 months but showed
inadequate therapeutic response, as deﬁned by less than 50%
improvement in psoriasis area and severity index (PASI) 50,
compared to baseline after 6 months or less than PASI25
improvement after 3 months in our hospital between 2006 and
2012. Patients also met the following national medical insurance
reimbursement criteria: (1) age 18 years old with a clinical
diagnosis of plaque-type psoriasis vulgaris for more than 6
months, (2) baseline PASI above 10 prior to etanercept and
adalimumab injection, (3) psoriasis affecting more than 10% body
surface area, and (4) inadequate response, contraindicated or
intolerant to narrow-band ultraviolet B or psoralen ultraviolet A
phototherapy at least twice a week for 3 months and to at least
two of the three conventional systemic agents including meth-
otrexate (up to 15 mg/wk), acitretin, and cyclosporine (up to
5 mg/kg/d).n. Published by Elsevier Taiwan LLC. All rights reserved.
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including age, sex, height, weight, disease duration, previous
systemic treatments, reasons fordiscontinuing systemic treatments,
and types of PsA. For evaluation of scalp lesions, signs of scalp
psoriasis (erythema, thickness, and scaliness) were scored using
a ﬁve-point scale (0 ¼ absent; 1 ¼mild; 2 ¼moderate; 3 ¼ severe;
4 ¼ very severe). Adalimumab 40 mg injections were given every 2
weeks with a loading dose of 80 mg. Patients were evaluated
monthly for safety and effectiveness. PASI, physician global assess-
ment (PGA), and scores of scalp lesions were calculated atWeeks 12
and 24. Patients were also asked to compare the efﬁcacy of eta-
nercept and adalimumab on PsA subjectively at Week 24.
Prior to the treatment, patients were checked for the presence of
hepatitis B virus surface antigen, hepatitis C virus (HCV) antibody,Table 1 Basic demographic and psoriatic characteristics of the patients.
No. Sex/age (y) Height (cm)/
weight (kg)/BMI
History of
psoriasis (y)
Other systemic
diseases
Previou
1 M/46 155/70/29.1 7 HCV carrier MTX (p
Subarachnoid
hemorrhage
Cyclosp
due to p
Acitreti
NBUVB
2 F/59 158/73/29.2 10 Nil MTX (se
NBUVB
Acitreti
3 F/33 161/61/23.5 27 Nil MTX (n
NBUVB
4 M/34 171/85/29.1 22 Iridocyclitis MTX (e
NBUVB
Acitreti
Cyclosp
5 M/46 172/64/21.6 11 Nil MTX (p
NBUVB
Acitreti
Cyclosp
6 M/50 174/88/29.1 17 Nil MTX (p
liver fu
NBUVB
Acitreti
Cyclosp
deterior
7 M/25 168/80/28.3 3 Hyperthyroidism MTX (p
NBUVB
Acitreti
8 F/47 159/80/31.6 23 Nil PUVA (g
MTX (e
and poo
Acitreti
Cyclosp
9 M/49 170/83/28.7 29 HBV carrier Isotretin
Uveitis Acitreti
UVB (in
PUVA (f
but efﬁ
10 M/52 168/70/24.8 20 CRF MTX (p
Hypertension NBUVB
Hyperurecemia Acitreti
Dyslipidemia Cyclosp
elevate
11 M/26 170/77/26.6 12 Nil Acitreti
NBUVB
Cyclosp
12 M/41 173/75/25.1 15 HBV carrier NBUVB
PUVA (n
Acitreti
Cyclosp
13 M/52 178/62/19.6 0.9 ESRD NBUVB
HCV carrier Acitreti
Type 2 DM MTX (m
liver fu
CRF ¼ chronic renal failure; ESRD ¼ end-stage renal disease; HBV ¼ hepatitis B virus; H
radiation; PUVA ¼ psoralen and ultraviolet A radiation; type 2 DM ¼ type 2 diabetes mand latent tuberculosis (TB) by chest X-ray and Quantiferon TB
Gold. Other concomitant major diseases were also recorded.
Results
Demographics
Thirteen patients were enrolled in the study. Baseline demo-
graphics were as followed: male-to-female ratio 10:3, mean age
43.1 years (range 25e59 years), mean body mass index (BMI) 26.6,
mean psoriatic disease duration 15.1 years (range 0.9e29 years),
and all patients having PsA (Table 1). There were six patients with
peripheral arthropathy, four with spondyloarthritis, and three with
mixed type.s systemic therapy for psoriasis Quantiferon TB
Gold examinations
Psoriatic arthritis
oor response) Positive Yes (peripheral)
orine (for 8 mo, discontinued
oor response)
n (poor response)
(intolerance)
vere GI side effects: nausea) Negative Yes (mixed)
(poor response)
n (severe desquamations and chelitis)
o response) Negative Yes (central)
(intolerance)
ffective but intolerable malaise) Negative Yes (mixed)
(no response)
n (no response)
orine (no response)
oor response) Negative Yes (central)
(intolerable itch)
n (poor response)
orine (poor response)
revious history of elevated
nction, for 7 y)
Negative Yes (central)
(intolerance itch)
n (no response)
orine (poor response,
ated renal function)
oor response) Negative Yes (central)
(poor response)
n (poor response)
ood response) Negative Yes (mixed)
levated liver function
r response)
n (poor response)
orine (poor response)
oin (poor response) Negative Yes (peripheral)
n (chelitis)
tolerable to itch)
or 2 y, effective initially,
cacy decreases later)
oor response) Negative Yes (peripheral)
(poor response)
n (poor response)
orine (poor response and
d blood pressure)
n (no response) Negative Yes (peripheral)
(no response)
orine (poor response)
(no response) Negative Yes (peripheral)
o response)
n (intolerable due to chelitis)
orine (for 31 mo)
(burn) Negative Yes (peripheral)
n (abnormal liver function)
ucositis, diarrhea, abnormal
nction, bone marrow suppression)
CV ¼ hepatitis C virus; MTX ¼ methotrexate; NBUVB ¼ narrow-band ultraviolet B
ellitus; UVB ¼ ultraviolet B radiation.
Table 2 Scalp scores while on etanercept and adverse events.
No. Scalp scores while on etanercept Adverse events of etanercept and
concomitant oral systemic agents
Five-point scale (0 ¼ absent;
1 ¼ mild; 2 ¼ moderate;
3 ¼ severe; 4 ¼ very severe)
Week
0 12 24 36 48 60 72
1 4 1 0 0 1 1 0 Elevated liver function (suspect
MTX-related); Weeks 36e48
along with MTX
2 3 0 0 0 0 Increased nevus
3 3 2 Nil; etanercept 50 mg BIW
for 3 mo (double dose)
4 4 2 2 Nil
5 3 1 2 2 2 Nil
Weeks 36e48 along with MTX
6 4 2 2 Nil
Weeks 0e24 along with MTX
7 3 2 3 Nil
8 3 2 Nil
9 2 1 1 0 0 Elevated liver function and
resistant strain of HBV found
after 3 mo of adalimumab therapy
10 2 2 2 1 1 1 Nil; Weeks 0e60 along with MTX,
salazine, and colchicine
11 4 2 1 Nil
12 1 1 3 Nil
13 2 2 Nil
HBV ¼ hepatitis B virus; MTX ¼ methotrexate.
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were hepatitis B virus (HBV) carriers, and three had multiple
comorbidities. All patients received chest X-ray and Quantiferon TB
Gold examinations. One patient (Patient 1) had latent TB and was
under isoniazid (300 mg/d) prophylaxis therapy for 9 months,
according to the local guideline.
Clinical response to etanercept and causes of etanercept
discontinuation
Eight patients (Patients 1, 3, 4, 7, 9, 11, 12, and 13) were in the
subgroup of primary loss of efﬁcacy or nonresponders. Five patients
(Patients 2, 5, 6, 8, and 10) had good response at ﬁrst but lost
therapeutic response later and were listed under secondary loss of
efﬁcacy subgroup. Patient 8 had clinical improvement during the
ﬁrst (2 months) and second (6 months) courses of etanercept
therapy, but she lost the efﬁcacy during the third course. She too
was included in the subgroup of secondary loss of efﬁcacy. Overall,
13 patients were switched to adalimumab therapy due to nonre-
sponse or loss of response, but none for adverse events.
The trend of PASI scores is shown in Figure 1. PASI scores, PGA
scores, and mean PASI reduction are listed in supplement Table 1.
The scalp scores and adverse events are listed in Table 2.
At Week 12, seven patients (53.8%) had at least PASI25 and two
(15%) had at least PASI50. At Week 24, ﬁve patients (50%) had at
least PASI25 and two (20%) had at least PASI50. (Three patients
lacked PASI scores at Week 24.)
Clinical response to adalimumab
At Week 12, one patient (7%) had at least PASI90, two (15%) had at
least PASI75, four (31%) had at least PASI50, and eight (61.5%) had at
least PASI25 response (the trend of PASI scores is shown in Figure 2;
PASI scores and PGA scores are shown in supplement Table 2).
At Week 24, two patients (15%) had at least PASI90, three (23%)
had at least PASI75, six (46%) had at least PASI50, and nine (69%)
had at least PASI25 response (the trend of PASI scores is shown in
Figure 2; PASI scores and PGA scores are shown in supplement
Table 2). Comparing the numbers of at least PASI25 and at least
PASI50, the clinical response to adalimumabwas found to be better
than etanercept at Weeks 12 and 24 in our series.
Mean PASI reduction of patients with primary loss of efﬁcacy
was 29.2 at Week 12 and 34.075 at Week 24. Mean PASI
reduction of patients with secondary loss of efﬁcacy was 38.92 at
Week 12 and42.26 at Week 24. AtWeek 12, two patients (25%) in
the group of primary loss of efﬁcacy and two (40%) in the group of
secondary loss of efﬁcacy achieved at least PASI50 response. At
Week 24, three patients (37.5%) in the group of primary loss ofFigure 1 Trend in PASI scores of etanercept therapy. PASI ¼ psoriasis area and severity
index.efﬁcacy and three (60%) in the group of secondary loss of efﬁcacy
achieved at least PASI50 response (Table 3). Patients with
secondary loss of efﬁcacy to etanercept seemed to respond better
than those with primary loss of efﬁcacy. However, a deﬁnitive
conclusion is difﬁcult because of limited number of participants in
this case series.
Only one patient (Patient 3) had concomitant oral methotrexate
from Week 0 to Week 24 during adalimumab therapy and showed
poor response to adalimumab. Other patients received only adali-
mumab therapy.
Patient 7 had dramatic clinical improvement with mean PASI
reduction of 100% at Week 24 compared to that at Week
0 (Figure 3).
Scalp response to adalimumab
Because of the reported good response of etanercept on scalp
psoriasis, the effectiveness of both agents on scalp lesions was
assessed separately. Ten patients had decreased scores after eta-
nercept treatment despite an inadequate overall PASI response,Figure 2 Trend in PASI scores of adalimumab therapy. PASI ¼ psoriasis area and
severity index.
Table 3 Mean PASI reduction while on adalimumab therapy.
No. Secondary loss
of efﬁcacy
Concomitant oral
systemic agents
Compare Week 12 to
Week 0 mean PASI
score change (%)
At Week 12 Compare Week 24 to
Week 0 mean PASI
score change (%)
At Week 24
PASI25 PASI50 PASI75 PASI90 PASI25 PASI50 PASI75 PASI90
1 No No 50.8 þ þ   29.0% þ   
2 Yes No 83.7 þ þ þ  57.9% þ þ  
3 No Methotrexate from
Week 0 to Week 24
39.0 þ    0%    
4 No No þ30.3     þ21.3%    
5 Yes No 94.9 þ þ þ þ 51.9% þ þ  
6 Yes No 2.8     5.6%    
7 No No 74.1 þ þ   100% þ þ þ þ
8 Yes No 14.6     44.2% þ   
9 No No 40.6 þ    93.1% þ þ þ þ
10 Yes No þ1.4     51.7% þ þ  
11 No No 46 þ    82.5% þ þ þ 
12 No No 45.1 þ    37.8% þ   
13 No No þ31.6     þ48.5%    
PASI ¼ psoriasis area and severity index.
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treatment. There was no signiﬁcant difference between thera-
peutic efﬁcacies of etanercept and adalimumab on scalp lesions
(Table 4).Figure 3 Patient 7 experienced dramatic improvementArthralgia response to adalimumab
Most patients reported similar therapeutic effects of etanercept and
adalimumab on arthralgia. Three patients (Patients 2, 3, and 6)with adalimumab: (A) at baseline; (B) at Week 24.
Table 4 Trend in scalp scores and arthralgia on adalimumab therapy.
No. Secondary
loss of
efﬁcacy
Scalp scores while on adalimumab Self-reported better
improvement of arthralgia
while on adalimumab
than on etanercept
Five-point scale (0 ¼ absent;
1 ¼ mild; 2 ¼ moderate;
3 ¼ severe; 4 ¼ very severe)
Week
0 12 24
1 No 0 0 0 Same
2 Yes 1 0 3 Yes
3 No 2 2 3 Yes
4 No 2 3 2 Etanercept has better
effects
5 Yes 2 0 0 Same
6 Yes 3 2 2 Yes
7 No 3 1 0 Same
8 Yes 3 2 1 Same
9 No 2 1 0 Same
10 Yes 3 1 1 Same
11 No 2 1 1 Same
12 No 2 2 2 Same
13 No 2 2 2 Same
T.-S. Wang, T.-F. Tsai / Dermatologica Sinica 31 (2013) 11e18 15preferred adalimumab and one patient (Patient 4) preferred eta-
nercept (Table 4).
Safety proﬁles of adalimumab
No severe adverse events were recorded in our series. Only three
patients had mild to moderate adverse effects (Patients 1 and 9 had
elevated liver function tests and Patient 2 had increased nevi).
Patient 1, an HCV carrier, was treated alongwithmethotrexate from
Week 36 to Week 48. Patient 9, an HBV carrier, was under eta-
nercept therapy for 48 weeks and had been treated with lam-
ivudine (100 mg daily) for 24 weeks prior to adalimumab use. The
patient’s HBV viral load was below detection limit (<10 IU/mL) and
the liver function tests were all within normal limits during eta-
nercept therapy. However, elevated liver function test and HBV viral
load (5.21  103 IU/mL) with resistant strain of HBV were found
after 3 months of adalimumab therapy, so lamivudine was replaced
with adefovir dipivoxil (10 mg every other day) plus lamivudine
(100 mg every other day) for the following 6 months until the
present time. Patients 9 and 12 patients were undergoing regular
follow-ups with liver function blood tests every 3 months and
abdomen sonography examinations every 6 months.
Discussion
Although both etanercept and adalimumab are TNF antagonists,
they differ in their structures and maybe also in their mode of
action. Adalimumab is a fully humanized monoclonal antibody that
binds to soluble and membrane-bound TNF-alpha, while eta-
nercept is a fusion protein that binds to soluble TNF-alpha and TNF-
beta. Antidrug antibodies have been reported to result in secondary
loss of efﬁcacy for adalimumab, but not for etanercept.1 Results
from the pivotal trials show a better PASI75 response of adalimu-
mab compared to etanercept in psoriasis and PsA.2 However, there
are no head-to-head controlled studies to compare the therapeutic
efﬁcacy of these two agents in psoriasis or PsA. Failure in adali-
mumab does not preclude the treatment response of etanercept,
and vice versa.3e13 Genetic variation in the binding site of one of the
agents or genetic variation within the TNF-a pathway may inﬂu-
ence the effect of another agent.14e18
Reports on the therapeutic response of etanercept and adali-
mumab in psoriasis are few in Asia.19 One retrospective study in
Taiwan shows 47% reduction in mean PASI at Week 12 and 61% atWeek 24, and only 26% and 37% patients achieve at least PASI75
response at Weeks 12 and 24, respectively, after etanercept treat-
ment.20 This PASI75 response of etanercept is lower than the
pivotal placebo-controlled trials.21e26 Similarly, in another report
from Taiwan, the percentage of patients who met PASI75 response
after etanercept treatment was only 13.6% and 14.3% at Weeks 12
and 24, respectively.27
The approved dose of etanercept for psoriasis in Taiwan is 25mg
administered BIW, but 50 mg administered BIW could be used for
the ﬁrst 3 months to treat a severe and unstable course of psori-
asis.20 Our study included patients who had received etanercept 25
or 50 mg BIW subcutaneous injection for at least 3 months. A large-
scale study (PRESTA) had revealed more rapid clearance of skin
lesions in those receiving etanercept 50 mg BIW compared with
50 mg QW. Although the percentage of patients with PASI75
response was higher for the 50 mg BIW group at either Week 12 or
Week 24, the mean PASI reduction did not show a statistical
signiﬁcance at Week 24.28 Further Asia-Paciﬁc subgroup analysis of
PRESTA study also revealed no statistically signiﬁcant difference in
efﬁcacy between the two doses in terms of PASI75 response at
Week 24.29 In our routine practice, no statistically signiﬁcant
differences in mean PASI improvement were found between the
50 mg BIW and 50 mg QWgroups at any time point up to 24 weeks
except atWeek 2.20 Thus, the use of higher initial dose of etanercept
for psoriasis is needed only for selected cases in Taiwan.
One pivotal study of adalimumab in the USA and Canada, which
included 147 psoriatic patients, has shown PASI75 response in 53%
and 80% of patients taking 40 mg adalimumab every other week
and weekly, respectively, at Week 12 after an initial loading dose of
80 mg.30 Another pivotal study in North America and Germany has
shown that 71% psoriatic patients taking 40 mg adalimumab every
other week achieve PASI75 response at Week 16.31 In Japan, one
double-blind, placebo-controlled study has shown PASI75 response
rates of 62.8% and 57.9% after treatment with adalimumab 40 mg
every other weekwith and without loading dose, respectively, after
16 weeks.32 Another study from a single community-based hospital
in Japan has shown that 81.8% patients receiving adalimumab
40 mg every other week without loading achieve PASI75 response
at Week 16.33 The treatment response is comparable. In Taiwan,
although no ofﬁcial trial exists, 66% and 74% patients with mild to
moderate psoriasis have achieved subject global assessment score
and PGA score of at least marked improvement (greater than 50%
improvement) after 12 weeks of adalimumab (40 mg subcutane-
ously every other week without a loading dose) treatment.34
The efﬁcacy of switching to a second TNF antagonist after failing
the ﬁrst TNF inhibitor has been studied mostly in patients with
rheumatoid arthritis or ankylosing spondylitis.35e45 In evaluating
the effects of biologic switch on patients with psoriasis, primary
failure is deﬁned as patients not achieving PASI50 at Week 12 and
secondary failure is deﬁned as a loss of response in patients who
achieved a PASI50 response at Week 12. In studies that focus on
switching from etanercept to adalimumab, as in our study,
80e100% patients achieve at least PASI50 and 33e87% patients
achieve at least PASI75 at Week 12, and 83% patients achieve at
least PASI50 and 55e83% patients achieve at least PASI75 at Week
24.4e8 The wide ranges of difference may be explained by differ-
ences in washout periods, dosing regimens, baseline severity, prior
treatment, and use of concomitant medication. Our results seem to
be less impressive compared to the previous reports (Table 5).
Clinical response of psoriasis to both etanercept and adalimu-
mab is less impressive in our series compared to previous reports.
The lower PASI75 response in Taiwan reports may be due to the
known difference between clinical trials and practical uses.20,27 In
addition, it may be due to a higher percentage of high-need and
recalcitrant patients because of the stringent reimbursement
Table 5 Studies on switchers from etanercept to adalimumab in psoriasis.
No. Adalimumab
dosing
Loading
double
dose at
Week 0
Concomitant oral
systemic agent
(%)
Follow-up
interval
(wk)
Outcome Comment
PASI50 PASI75 PASI90 PASI50 PASI75 PASI90
Martyn-Simmons
et al4
5 40 mg weekly Yes 0 12 Week 12 All primary etanercept
failures (at 12 wk) after
treatment with etanercept
50 mg twice weekly for
12 wk
80 40 20
Lecluse et al5 3 40 mg weekly
or 40 mg
fortnightly
Not
stated
66 From 1
to 7
mo
(variable)
Final PASI response compared
with baseline (%)
Patients who switched
biologic agent due to
treatment failure; all
three patients who
switched to
adalimumab had
failed on etanercept
Along with
MTX
100 33 33
Ryan et al6 23 40 mg
fortnightly
Yes Not stated 48 Week 16 Week 24
 32   53 
Woolf et al7 14 40 mg
fortnightly
Yes 29 16 Week 16 Seven patients had failed on
etanercept only, and seven
had received etanercept and
at least one other biologic
agent prior to adalimumab
Three patients
with MTX and
one patient with
cyclosporine
64 29 7
Papoutsaki et al8 30 40 mg weekly No 0 24 Week 12 Week 24 All patients who previously
used etanercept combined
with inﬂiximab and/or
efalizumab discontinued the
therapy due to loss of effects
or adverse effects
90 87 70 83 83 77
Our series 13 40 mg
fortnightly
Yes 7.7 24 Week 12 Week 24 Eight patients had primary
failures31 15 7 46 23 15
MTX ¼ methotrexate; PASI ¼ psoriasis area and severity index.
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human leukocyte antigen found in Taiwan and those found in
Western countries may also be important.46e48
A randomized controlled comparative study (CHAMPION) has
shown that the response to adalimumab is rapid with a 57%
improvement in mean PASI observed at Week 4.49Another phase II/
III randomized controlled study in Japan has also shown that ada-
limumab has a rapid onset of action (early at 4 weeks), and the
percentages of patients achieving PASI75 continue to increase until
Week 16 and are maintained through Week 24.50 However, our
series show a trend of increased therapeutic improvement from
Week 12 to Week 24. It is likely that longer time is required to
achieve full therapeutic response in recalcitrant patients, as in case
of our patients.
Studies on the effects of biologic switch on patients with
psoriasis remain limited in the Asia-Paciﬁc region, and the efﬁcacy
of adalimumab after switching from etanercept is of special interest
in Taiwan. It is because etanercept was reimbursed for psoriasis 8
months prior to adalimumab. The result of this case series may
serve as an important reference for clinicians when considering the
next step of treatment after etanercept failure.
Patients who showed inadequate primary response to eta-
nercept also seemed to respond less favorably to subsequent ada-
limumab treatment. There may be several possible reasons. First, it
is likely that other cytokines may be more important in these
patients. In fact, recent studies suggest Th17 to be at least as
important as TNF in the pathogenic pathway of psoriasis.51 Second,
in one study, non-neutralizing antietanercept antibodies were re-
ported in up to 18% of patients taking etanercept for psoriasis over
a period of 96 weeks.52 However, it is unknown if prior use of
etanercept will trigger an increased production of antiadalimumab
antibodies. Only one study has shown that patients of rheumatoid
arthritis who previously formed antibodies against inﬂiximab are
more likely to develop antibodies against adalimumab53 and that it
is more likely that some patients are more prone to develop animmune response, possibly related to the genetic background. In
addition, 0.6e12% psoriatic patients would develop anti-
adalimumab antibodies.1 It has been found from studies on PsA that
antiadalimumab antibodies develop in a minority of patients, and
are associated with lower serum levels of adalimumab and
diminished clinical response to treatment.54 Third, the efﬁcacy of
anti-TNF antagonists would diminish with time, and the drug
survival of patients who previously failed one or more anti-TNF
antagonists is more poor compared with the anti-TNF antago-
nists-naive patients.55
The scalp is one of the most common sites affected by psori-
asis,56 and scalp psoriasis has a substantial impact on the patients’
quality of life.57 Previous studies have revealed that etanercept
exerts impressive therapeutic effects on scalp lesions of psori-
asis.58,59 Although adalimumab can be effective in patients who are
poor responders to etanercept, it is not more effective in those with
scalp psoriasis in our case series. The exact reason is unknown, but
it is possible that either etanercept has a slightly different mode of
action60 or scalp is an easy target for both agents. For the nonre-
sponders of both agents, a master cytokine other than TNF may be
presented.
There are no published randomized controlled trials that
provide a head-to-head comparison of the effectiveness of the
three TNF antagonists (adalimumab, etanercept, and inﬂiximab) in
treating patients with PsA.61e65 Some authors have reported that
etanercept might have better effects in controlling PsA.66e68
However, in our series, subjective improvement in arthralgia with
adalimumab was comparable to that with etanercept.
No severe adverse events were recorded in our series, but one
HCV carrier and one HBV carrier had elevated liver function tests.
An increased risk for HBV carriers has been found in patients with
psoriasis in Taiwan.69 Nevertheless, the use of anti-TNF-alpha
therapy for HBV carriers with psoriasis or PsA is still controver-
sial. Due to a lack of consensus in managing HBV carriers with
psoriasis or PsA, antiviral prophylaxis is usually used in conjunction
T.-S. Wang, T.-F. Tsai / Dermatologica Sinica 31 (2013) 11e18 17with anti-TNF therapy, based on the suggestions for HBV carriers
receiving chemotherapeutic agents for their malignancies.70
However, these patients may develop resistance to antiviral
agents, especially lamivudine, during long-term use and show
subsequent elevation of aspartate aminotransferase/alanine
aminotransferase (AST⁄ALT) levels.71 In addition, different anti-TNF
antagonists may have different impacts on HBV reactivation.
Inﬂiximab is associated with more cases of HBV activation
compared to etanercept or adalimumab.72 This may be due to more
pronounced clearance of TNF-a, as the drug binds both soluble and
membrane-bound TNF-a and is also cytotoxic for TNF-expressing
cells.73 But there are no data comparing between the impact of
etanercept and adalimumab on HBV. The increased HBV viral load
after switching from etanercept to adalimumab in our patient
might be due to either a time factor after prolonged antiviral
treatment or a stronger immunosuppressive effect of adalimumab.
However, it seems safe to use adalimumab for treating psoriatic
patients who are HBV carriers under closer monitoring.
Conclusion
This is a preliminary report of our experience of reimbursed ada-
limumab use for psoriasis in Taiwan. This study was limited by the
relatively short study duration and small sample size. A national
registry of all biologic users is needed to assess the safety and
efﬁcacy of adalimumab. However, long-term results are unlikely to
be gathered from this registry because of the strict reimbursement
criteria in Taiwan, which necessitate discontinuation of biologics
after 6e12 months for the PASI50 responders. Adalimumab has
similar safety proﬁles as etanercept and can be effective in some
psoriatic patients who have failed prior etanercept therapy.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://dx.
doi.org/10.1016/j.dsi.2012.07.004.
References
1. Mössner R, Schön MP, Reich K. Tumor necrosis factor antagonists in the therapy
of psoriasis. Clin Dermatol 2008;26:486e502.
2. Gelfand JM, Wan J, Callis Dufﬁn K, et al. Comparative effectiveness of
commonly used systemic treatments or phototherapy for moderate to severe
plaque psoriasis in the clinical practice setting. Arch Dermatol 2012;
148:487e94.
3. Van Lümig PP, Lecluse LL, Driessen RJ, et al. Switching from etanercept to
adalimumab is effective and safe: results in 30 patients with psoriasis with
primary failure, secondary failure or intolerance to etanercept. Br J Dermatol
2010;163:838e46.
4. Martyn-Simmons CL, Green L, Ash G, et al. Adalimumab for psoriasis patients
who are non-responders to etanercept: open-label prospective evaluation. J Eur
Acad Dermatol Venereol 2009;23:1394e7.
5. Lecluse LL, de Groot M, Bos JD, Spuls PI. Experience with biologics for psoriasis
in daily practice: switching is worth a try. Br J Dermatol 2009;161:948e51.
6. Ryan C, Kirby B, Collins P, Rogers S. Adalimumab treatment for severe recal-
citrant chronic plaque psoriasis. Clin Exp Dermatol 2009;34:784e8.
7. Woolf RT, Smith CH, Robertson K, Barker JN. Switching to adalimumab in
patients with moderate to severe psoriasis who have failed on etanercept:
a retrospective case cohort study. Br J Dermatol 2010;163:889e92.
8. Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis
and psoriatic arthritis: an open-label study in 30 patients previously treated
with other biologics. J Am Acad Dermatol 2007;57:269e75.
9. Ortonne JP, Chimenti S, Reich K, et al. Efﬁcacy and safety of adalimumab in
patients with psoriasis previously treated with anti-tumour necrosis factor
agents: subanalysis of BELIEVE. J Eur Acad Dermatol Venereol 2011;25:1012e20.
10. Vender R. An open-label, prospective cohort pilot study to evaluate the efﬁcacy
and safety of etanercept in the treatment of moderate to severe plaque
psoriasis in patients who have not had an adequate response to adalimumab.
J Drugs Dermatol 2011;10:396e402.
11. Ormerod AD. Switching biologics for psoriasis. Br J Dermatol 2010;163:667e9.
12. Saccomani C, Penz S, Guerre-Schmidt R, et al. Biological therapy for psoriasis:
practical experience at a French dermatology unit. Ann Dermatol Venereol
2009;136:877e82.13. Mazzotta A, Esposito M, Costanzo A, Chimenti S. Efﬁcacy and safety of eta-
nercept in psoriasis after switching from other treatments: an observational
study. Am J Clin Dermatol 2009;10:319e24.
14. Lie E, van der Heijde D, Uhlig T, et al. Effectiveness of switching between TNF
inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann
Rheum Dis 2011;70:157e63.
15. Blom M, Kievit W, Fransen J, et al. The reason for discontinuation of the ﬁrst
tumor necrosis factor (TNF) blocking agent does not inﬂuence the effect of
a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol
2009;36:2171e7.
16. Lee YH, Ji JD, Song GG. Tumor necrosis factor-alpha promoter -308 A/G poly-
morphism and rheumatoid arthritis susceptibility: a metaanalysis. J Rheumatol
2007;34:43e9.
17. Padyukov L, Lampa J, Heimburger M, et al. Genetic markers for the efﬁcacy of
tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum
Dis 2003;62:526e9.
18. Kastbom A, Bratt J, Ernestam S, et al. Fc-gamma receptor type IIIA genotype and
response to tumor necrosis factor alpha-blocking agents in patients with
rheumatoid arthritis. Arthritis Rheum 2007;56:448e52.
19. Tsai TF, Yeh TY. The use of biologics for psoriasis in Asia-Paciﬁc region. Curr
Rheumatol Rev 2009;5:149e52.
20. Chiu HY, Wang TS, Cho YT, Tsai TF. Etanercept use for psoriasis in Taiwan:
a case series study. Int J Dermatol February 20, 2012. http://dx.doi.org/10.1111/
j.1365-4632.2011.05273.x.
21. Gordon K, Korman N, Frankel E, et al. Efﬁcacy of etanercept in an integrated
multistudy database of patients with psoriasis. J Am Acad Dermatol
2006;54:S101e11.
22. Gottlieb AB, Leonardi CL, Goffe BS, et al. Etanercept monotherapy in patients
with psoriasis: a summary of safety, based on an integrated multistudy data-
base. J Am Acad Dermatol 2006;54:S92e100.
23. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as
monotherapy for psoriasis. Arch Dermatol 2003;139:1627e32.
24. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in
patients with psoriasis. N Engl J Med 2003;349:2014e22.
25. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial
of etanercept in psoriasis: safety, efﬁcacy, and effect of dose reduction. Br J
Dermatol 2005;152:1304e12.
26. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efﬁcacy of 50 mg of
etanercept twice weekly in patients with psoriasis. Arch Dermatol
2007;143:719e26.
27. Wu YF, Huang YH. The efﬁcacy and safety of etanercept in treating patients
with recalcitrant psoriasis. 37th Annual Meeting of the Taiwanese Dermato-
logical Association, November 26e27, 2011. Poster RR02. Taipei, Taiwan.
28. Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens
for treatment of psoriasis and psoriatic arthritis: PRESTA randomized double-
blind multicenter trial. BMJ 2010 Feb 2;340:c147. http://dx.doi.org/10.1136/
bmj.c147.
29. Tsai TF, Youn J, Foley P, et al. PRESTA: Asia-Paciﬁc subanalysis; unpublished
data presented at the Asian Academy of Dermatology and Venereology,
November 6e7, 2009, Hanoi.
30. Lecluse LL, Driessen RJ, Spuls PI, et al. Extent and clinical consequences of
antibody formation against adalimumab in patients with plaque psoriasis. Arch
Dermatol 2010;146:127e32.
31. Haitz KA, Kalb RE. Inﬂiximab in the treatment of psoriasis in patients previ-
ously treated with etanercept. J Am Acad Dermatol 2007;57:120e5.
32. Asahina A, Nakagawa H, Etoh T, Ohtsuki M. Adalimumab M04-688 Study
Group. Adalimumab in Japanese patients with moderate to severe chronic
plaque psoriasis: efﬁcacy and safety results from a Phase II/III randomized
controlled study. J Dermatol 2010;37:299e310.
33. Noda S, Mizuno K, Adachi M. Treatment effect of adalimumab and inﬂiximab in
Japanese psoriasis patients: results in a single community-based hospital.
J Dermatol 2012;39:265e8.
34. Chiu HY, Wang TS, Chung CY, Tsai TF. The effectiveness and safety of adali-
mumab in the treatment of non-reimbursed patients with mild-to-moderate
psoriasis. J Eur Acad Dermatol Venereol 2012;26:991e8.
35. Hjardem E, Østergaard M, Pødenphant J, et al. Do rheumatoid arthritis patients
in clinical practice beneﬁt from switching from inﬂiximab to a second tumor
necrosis factor alpha inhibitor? Ann Rheum Dis 2007;66:1184e9.
36. Wick MC, Ernestam S, Lindblad S, et al. Adalimumab (Humira) restores clinical
response in patients with secondary loss of efﬁcacy from inﬂiximab (Remicade)
or etanercept (Enbrel): results from the STURE registry at Karolinska University
Hospital. Scand. J Rheumatol 2005;34:353e8.
37. Haraoui B, Keystone EC, Thorne JC, et al. Clinical outcomes of patients with
rheumatoid arthritis after switching from inﬂiximab to etanercept. J Rheumatol
2004;31:2356e9.
38. Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-
tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha
agent in patients with rheumatoid arthritis: results from a large UK national
cohort study. Arthritis Rheum 2007;56:13e20.
39. Bennett AN, Peterson P, Zain A, et al. Adalimumab in clinical practice.
Outcome in 70 rheumatoid arthritis patients, including comparison of
patients with and without previous anti-TNF exposure. Rheumatology
2005;44:1026e31.
40. Ang HT, Helfgott S. Do the clinical responses and complications following
etanercept or inﬂiximab therapy predict similar outcomes with the other
T.-S. Wang, T.-F. Tsai / Dermatologica Sinica 31 (2013) 11e1818tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?
J Rheumatol 2003;30:2315e8.
41. Cohen G, Courvoisier N, Cohen JD, et al. The efﬁciency of switching from
inﬂiximab to etanercept and vice-versa in patients with rheumatoid arthritis.
Clin Exp Rheumatol 2005;23:795e800.
42. Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheu-
matoid arthritis beneﬁts from switching to rituximab versus alternative anti-
tumour necrosis factor (TNF) agents after previous failure of an anti-TNF
agent? Ann Rheum Dis 2010;69:387e93.
43. Karlsson JA, Kristensen LE, Kapetanovic MC, et al. Treatment response to
a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis
Treatment Group Register. Rheumatology 2008;47:507e13.
44. Van Vollenhoven RF. Switching between anti-tumour necrosis factors: trying
to get a handle on a complex issue. Ann Rheum Dis 2007;66:849e51.
45. Conti F, Ceccarelli F, Marocchi E, et al. Switching tumour necrosis factor alpha
antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an
observational study over a 5-year period. Ann Rheum Dis 2007;66:1393e7.
46. Chiu HY, Huang PY, Jee SH, et al. Human leukocyte antigens polymorphism
among Chinese patients with chronic plaque psoriasis: subgroup analysis. Br J
Dermatol 2012;166:188e97.
47. Tsai TF, Hu CY, Tsai WL, et al. HLA-Cw6 speciﬁcity and polymorphic residues
are associated with susceptibility among Chinese psoriatics in Taiwan. Arch
Dermatol Res 2002;194:214e20.
48. Jee SH, Tsai TF, Tsai WL, et al. HLA-DRB1*0701 and DRB1*1401 are associated
with genetic susceptibility to psoriasis vulgaris in a Taiwanese population. Br J
Dermatol 1998;139:978e83.
49. Saurat JH, Stingl G, Dubertret L, et al. Efﬁcacy and safety results from the
randomized controlled comparative study of adalimumab vs. methotrexate vs.
placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;
158:558e66.
50. Asahina A, Nakagawa H, Etoh T, et al. Adalimumab in Japanese patients with
moderate to severe chronic plaque psoriasis: efﬁcacy and safety results from
a Phase II/III randomized controlled study. J Dermatol 2010;37:299e310.
51. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia
by TNF inhibition is associated with reduced Th17 responses. J Exp Med
2007;204:3183e94.
52. Tyring S, Poulin Y, Langley R, et al. A 96-week phase 3 study of safety and
efﬁcacy of etanercept 50 mg twice weekly in patients with psoriasis. 64th
Annual Meeting of the American Academy of Dermatology, March 3e7, 2006.
Poster. San Francisco, CA, USA.
53. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-inﬂiximab and anti-
adalimumab antibodies in relation to response to adalimumab in inﬂiximab
switchers and anti-tumour necrosis factor naïve patients: a cohort study. Ann
Rheum Dis 2010;69:817e21.
54. Van Kuijk AW, de Groot M, Stapel SO, Dijkmans BA, Wolbink GJ, Tak PP.
Relationship between the clinical response to adalimumab treatment and
serum levels of adalimumab and anti-adalimumab antibodies in patients with
psoriatic arthritis. Ann Rheum Dis 2010;69:624e5.
55. Burden AD. Drug survival rates for tumour necrosis factor-a antagonists in
psoriasis. Br J Dermatol 2011;164:940e1.
56. Chen HS, Tseng MP, Tsai TF. An epidemiologic study of Taiwanese psoriatic
patients in a single clinic. Dermatol Sin 2003;21:216e24.57. Crowley J. Scalp psoriasis: an overview of the disease and available therapies.
J Drugs Dermatol 2010;9:912e8.
58. TyringS, Bagel J, LyndeC, et al. Patient-reportedoutcomes inmoderate-to-severe
plaque psoriasis with scalp involvement: results from a randomized, double-
blind, placebo-controlled study of etanercept. J Eur Acad Dermatol Venereol
December 21, 2011. http://dx.doi.org/10.1111/j.1468-3083.2011.04394.x.
59. Bagel J, Lynde C, Tyring S, Kricorian G, Shi Y, Klekotka P. Moderate to
severe plaque psoriasis with scalp involvement: a randomized,
double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol
2012;67:86e92.
60. Wang F, Smith N, Maier L, et al. Etanercept suppresses regenerative hyperplasia
in psoriasis by acutely downregulating epidermal expression of IL-19, IL-20
and IL-24. Br J Dermatol 2012;167:92e102.
61. Gomez-Reino JJ, Carmona L. BIOBADASER Group. Switching TNF antagonists in
patients with chronic arthritis: an observational study of 488 patients over
a four-year period. Arthritis Res Ther 2006;8:R29. Epub 2006 Jan 6.
62. Genovese MC, Mease PJ, Thomson GT, et al. Safety and efﬁcacy of adalimumab
in treatment of patients with psoriatic arthritis who had failed disease modi-
fying antirheumatic drug therapy. J Rheumatol 2007;34:1040e50.
63. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained beneﬁts of inﬂiximab
therapy for dermatologic and articular manifestations of psoriatic arthritis:
results from the inﬂiximab multinational psoriatic arthritis controlled trial
(IMPACT). Arthritis Rheum 2005;52:1227e36.
64. MeasePJ, KivitzAJ, BurchFX, etal. Etanercept treatmentofpsoriatic arthritis: safety,
efﬁcacy, and effect on disease progression. Arthritis Rheum 2004;50:2264e72.
65. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of
patients with moderately to severely active psoriatic arthritis: results of
a double-blind, randomized, placebo-controlled trial. Arthritis Rheum
2005;52:3279e89.
66. Bhutani T, Koo J. Paradoxical worsening of psoriasis when switching from
etanercept to adalimumab: a case series. J Dermatol Treat 2011;22:75e8.
67. Migliore A, Bizzi E, Broccoli S, Laganà B. Indirect comparison of etanercept,
inﬂiximab, and adalimumab for psoriatic arthritis: mixed treatment
comparison using placebo as common comparator. Clin Rheumatol 2012;31:
133e7.
68. Bombardieri S, Ruiz AA, Fardellone P, et al, Research in Active Rheumatoid
Arthritis (ReAct) Study Group. Effectiveness of adalimumab for rheumatoid
arthritis in patients with a history of TNFantagonist therapy in clinical practice.
Rheumatology 2007;46:1191e9.
69. Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis
patients in a national database in Taiwan. J Dermatol Sci 2011;63:40e6.
70. Cho YT, Chen CH, Chiu HY, Tsai TF. Use of anti-tumor necrosis factor-a therapy
in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in
Taiwan. J Dermatol 2012;39:269e73.
71. Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy
induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis
2007;11:965e91.
72. Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in
hepatitis B surface antigen-positive patients: a literature review and potential
mechanisms of action. Clin Rheumatol 2010;29:1021e9.
73. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid
arthritis. N Engl J Med 2006;355:704e12.
